BCVA changes after suprachoroideal graft of autologous cells in Dry AMD

The idea of cell therapy using the systemic or local injection of stem/progenitor cells in the area of injury to treat multiple chronic disorders received close attention in the last decade (1-3). Our prior study showed in eyes affected by Dry AMD a significant improvement of ERG data, recorded after the suprachoroidal autologous graft (4, 5). Dry AMD is an atrophic retinal disease where the cells die progressively and irreversibly with a loss of central visual function (6-9).The growth factors are particular proteins able to block or slow down the processes of pro-grammed death (apoptosis) (10-15). Many human body cells are able to produce growth factors.